Cargando…

Mitochondrial Respiration Changes in R6/2 Huntington’s Disease Model Mice during Aging in a Brain Region Specific Manner

Mitochondrial dysfunction is crucially involved in aging and neurodegenerative diseases, such as Huntington’s Disease (HD). How mitochondria become compromised in HD is poorly understood but instrumental for the development of treatments to prevent or reverse resulting deficits. In this paper, we in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burtscher, Johannes, Di Pardo, Alba, Maglione, Vittorio, Schwarzer, Christoph, Squitieri, Ferdinando
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432063/ https://www.ncbi.nlm.nih.gov/pubmed/32751413 http://dx.doi.org/10.3390/ijms21155412

Ejemplares similares

A Rationale for Hypoxic and Chemical Conditioning in Huntington’s Disease
por: Burtscher, Johannes, et al.
Publicado: (2021)

Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model
por: Squitieri, Ferdinando, et al.
Publicado: (2015)

Nitric Oxide Dysregulation in Platelets from Patients with Advanced Huntington Disease
por: Carrizzo, Albino, et al.
Publicado: (2014)

Tractography of the Corpus Callosum in Huntington’s Disease
por: Phillips, Owen, et al.
Publicado: (2013)

Brain Region and Cell Compartment Dependent Regulation of Electron Transport System Components in Huntington’s Disease Model Mice
por: Burtscher, Johannes, et al.
Publicado: (2021)

DNA instability in replicating Huntington's disease lymphoblasts
por: Cannella, Milena, et al.
Publicado: (2009)

Changes of peripheral TGF-β1 depend on monocytes-derived macrophages in Huntington disease
por: Di Pardo, Alba, et al.
Publicado: (2013)

Glyco-sphingo biology: a novel perspective for potential new treatments in Huntington's disease
por: Di Pardo, Alba, et al.
Publicado: (2017)

Impaired Levels of Gangliosides in the Corpus Callosum of Huntington Disease Animal Models
por: Di Pardo, Alba, et al.
Publicado: (2016)

Dysfunctional mitochondrial respiration in the striatum of the Huntington’s disease transgenic R6/2 mouse model
por: Aidt, Frederik Heurlin, et al.
Publicado: (2013)

Impairment of blood-brain barrier is an early event in R6/2 mouse model of Huntington Disease
por: Di Pardo, Alba, et al.
Publicado: (2017)

Genetic Counseling in Huntington's Disease: Potential New Challenges on Horizon?
por: Migliore, Simone, et al.
Publicado: (2019)

Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date
por: Squitieri, Ferdinando, et al.
Publicado: (2015)

Safer Attitude to Risky Decision-Making in Premanifest Huntington’s Disease Subjects
por: D’Aurizio, Giulia, et al.
Publicado: (2019)

Sleep Quality and Related Clinical Manifestations in Huntington Disease
por: Maffi, Sabrina, et al.
Publicado: (2022)

De novo Synthesis of Sphingolipids Is Defective in Experimental Models of Huntington's Disease
por: Di Pardo, Alba, et al.
Publicado: (2017)

Deep White Matter in Huntington's Disease
por: Phillips, Owen, et al.
Publicado: (2014)

Current Diagnostic Methods and Non-Coding RNAs as Possible Biomarkers in Huntington’s Disease
por: Pellegrini, Miguel, et al.
Publicado: (2022)

Treatment with the Glycosphingolipid Modulator THI Rescues Myelin Integrity in the Striatum of R6/2 HD Mice
por: Pepe, Giuseppe, et al.
Publicado: (2023)

Motor phenotype is not associated with vascular dysfunction in symptomatic Huntington’s disease transgenic R6/2 (160 CAG) mice
por: Di Pardo, A., et al.
Publicado: (2017)

Aripiprazole in the treatment of Huntington’s disease: a case series
por: Ciammola, Andrea, et al.
Publicado: (2009)

The Opioid System in Temporal Lobe Epilepsy: Functional Role and Therapeutic Potential
por: Burtscher, Johannes, et al.
Publicado: (2017)

Current Pharmacological Management in Juvenile Huntington’s Disease
por: Robertson, Lisa, et al.
Publicado: (2012)

Sphingolipid Metabolism: A New Therapeutic Opportunity for Brain Degenerative Disorders
por: Di Pardo, Alba, et al.
Publicado: (2018)

Emotion recognition and inhibitory control in manifest and pre-manifest Huntington's disease: evidence from a new Stroop task
por: Hünefeldt, Thomas, et al.
Publicado: (2020)

Stimulation of Sphingosine Kinase 1 (SPHK1) Is Beneficial in a Huntington’s Disease Pre-clinical Model
por: Di Pardo, Alba, et al.
Publicado: (2019)

Major Superficial White Matter Abnormalities in Huntington's Disease
por: Phillips, Owen R., et al.
Publicado: (2016)

Pronounced α-Synuclein Pathology in a Seeding-Based Mouse Model Is Not Sufficient to Induce Mitochondrial Respiration Deficits in the Striatum and Amygdala
por: Burtscher, Johannes, et al.
Publicado: (2020)

Proenkephalin Derived Peptides Are Involved in the Modulation of Mitochondrial Respiratory Control During Epileptogenesis
por: Burtscher, Johannes, et al.
Publicado: (2018)

The G‐protein biased partial κ opioid receptor agonist 6′‐GNTI blocks hippocampal paroxysmal discharges without inducing aversion
por: Zangrandi, Luca, et al.
Publicado: (2016)

Cognitive and behavioral associated changes in manifest Huntington disease: A retrospective cross‐sectional study
por: Migliore, Simone, et al.
Publicado: (2021)

International Guidelines for the Treatment of Huntington's Disease
por: Bachoud-Lévi, Anne-Catherine, et al.
Publicado: (2019)

Asialoerythropoetin is not effective in the R6/2 line of Huntington's disease mice
por: Gil, Joana MAC, et al.
Publicado: (2004)

“Spazio Huntington”: Tracing the Early Motor, Cognitive and Behavioral Profiles of Kids with Proven Pediatric Huntington Disease and Expanded Mutations > 80 CAG Repeats
por: Graziola, Federica, et al.
Publicado: (2022)

Diagnostic properties of the Frontal Assessment Battery (FAB) in Huntington’s disease
por: Solca, Federica, et al.
Publicado: (2022)

GPER1 (GPR30) knockout mice display reduced anxiety and altered stress response in a sex and paradigm dependent manner
por: Kastenberger, Iris, et al.
Publicado: (2014)

Early defect of transforming growth factor β(1) formation in Huntington’s disease
por: Battaglia, Giuseppe, et al.
Publicado: (2011)

Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington’s disease
por: Di Pardo, Alba, et al.
Publicado: (2017)

IKKβ slows Huntington’s disease progression in R6/1 mice
por: Ochaba, Joseph, et al.
Publicado: (2019)

Cognitive Reserve in Early Manifest Huntington Disease Patients: Leisure Time Is Associated with Lower Cognitive and Functional Impairment
por: Migliore, Simone, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2ic7dpqnjd6cbcc3rph31cq3cr